



# Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study

*Diabetes Care* 2021;44:2107–2114 | <https://doi.org/10.2337/dc21-0476>

Bruce A. Perkins,<sup>1,2</sup> Leif Erik Lovblom,<sup>1</sup> Evan J.H. Lewis,<sup>1</sup> Vera Bril,<sup>3</sup> Maryam Ferdousi,<sup>4</sup> Andrej Orszag,<sup>1</sup> Katie Edwards,<sup>5</sup> Nicola Pritchard,<sup>5</sup> Anthony Russell,<sup>6</sup> Cirous Dehghani,<sup>5</sup> Danièle Pacaud,<sup>7</sup> Kenneth Romanchuk,<sup>7</sup> Jean K. Mah,<sup>7</sup> Maria Jeziorska,<sup>4</sup> Andrew Marshall,<sup>7</sup> Roni M. Shtein,<sup>8</sup> Rodica Pop-Busui,<sup>8</sup> Stephen I. Lentz,<sup>8</sup> Mitra Tavakoli,<sup>4,9</sup> Andrew J.M. Boulton,<sup>4</sup> Nathan Efron,<sup>5</sup> and Rayaz A. Malik<sup>4,10</sup>

## OBJECTIVE

Corneal nerve fiber length (CNFL) has been shown in research studies to identify diabetic peripheral neuropathy (DPN). In this longitudinal diagnostic study, we assessed the ability of CNFL to predict the development of DPN.

## RESEARCH DESIGN AND METHODS

From a multinational cohort of 998 participants with type 1 and type 2 diabetes, we studied the subset of 261 participants who were free of DPN at baseline and completed at least 4 years of follow-up for incident DPN. The predictive validity of CNFL for the development of DPN was determined using time-dependent receiver operating characteristic (ROC) curves.

## RESULTS

A total of 203 participants had type 1 and 58 had type 2 diabetes. Mean follow-up time was 5.8 years (interquartile range 4.2–7.0). New-onset DPN occurred in 60 participants (23%; 4.29 events per 100 person-years). Participants who developed DPN were older and had a higher prevalence of type 2 diabetes, higher BMI, and longer duration of diabetes. The baseline electrophysiology and corneal confocal microscopy parameters were in the normal range but were all significantly lower in participants who developed DPN. The time-dependent area under the ROC curve for CNFL ranged between 0.61 and 0.69 for years 1–5 and was 0.80 at year 6. The optimal diagnostic threshold for a baseline CNFL of 14.1 mm/mm<sup>2</sup> was associated with 67% sensitivity, 71% specificity, and a hazard ratio of 2.95 (95% CI 1.70–5.11;  $P < 0.001$ ) for new-onset DPN.

## CONCLUSIONS

CNFL showed good predictive validity for identifying patients at higher risk of developing DPN ~6 years in the future.

Diabetic peripheral neuropathy (DPN) is the most frequent long-term complication of diabetes (1). Current diagnostic criteria require the presence of clinical signs and symptoms and abnormal nerve conduction measurements, both of which are weighted toward abnormalities of the large fibers (2). However, these diagnostic tests do not reliably detect early damage to the small nerve fibers, which may

<sup>1</sup>Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada

<sup>2</sup>Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

<sup>3</sup>The Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Krembil Neuroscience Centre, Division of Neurology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada

<sup>4</sup>University of Manchester, Manchester, U.K.

<sup>5</sup>Queensland University of Technology, Brisbane, Queensland, Australia

<sup>6</sup>University of Queensland, Woolloongabba, Queensland, Australia

<sup>7</sup>Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada

<sup>8</sup>University of Michigan, Ann Arbor, MI

<sup>9</sup>Diabetes and Vascular Research Centre, NIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, U.K.

<sup>10</sup>Weill Cornell Medicine-Qatar, Doha, Qatar

Corresponding author: Bruce A. Perkins, [bruce.perkins@sinaihealth.ca](mailto:bruce.perkins@sinaihealth.ca)

Received 26 February 2021 and accepted 28 May 2021

This article contains supplementary material online at <https://doi.org/10.2337/figshare.14696808>.

© 2021 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/content/license>.

predate the large fiber abnormalities (3) and potentially represent an early subclinical phase of DPN. While thermal threshold and sudomotor testing and intraepidermal nerve fiber density allow an assessment of small fiber dysfunction and damage, the former are not widely available and the latter requires skin biopsy, an invasive procedure.

Corneal confocal microscopy (CCM) is a rapid, noninvasive, ophthalmic imaging tool that is comparable to skin punch biopsy in the diagnosis of DPN (4) and correlates with other established measures of small fiber neuropathy (5). In a large multinational cohort study, we established the diagnostic validity for CCM in the diagnosis of DPN (6). We previously showed that a rapid decline in corneal nerve fiber length (CNFL) was associated with the development of foot ulceration and Charcot foot, and recently we have shown that patients with diabetes with a more rapid decline in CNFL are at increased risk for the development and progression of DPN (7). Moreover, in two small cohort studies of patients with type 1 diabetes, we have previously demonstrated as a proof of concept that CNFL may have diagnostic validity to identify future incident DPN (8,9). Thus, it was proposed, but not yet confirmed, that a baseline measurement of CNFL may have diagnostic usefulness for predicting the future onset of DPN. This longitudinal, diagnostic, multinational consortium study aimed to provide robust evidence for the predictive diagnostic validity of CCM for the future onset of DPN in people with type 1 and type 2 diabetes.

## RESEARCH DESIGN AND METHODS

### Study Design

This was a planned longitudinal analysis by an international consortium of data from five separate cohorts pooled into a single prospective study (ClinicalTrials.gov identifier: NCT02423434). The study design and baseline characteristics of the study population have been previously reported (6). The diagnostic index test was CNFL quantification using CCM, and the reference standard for DPN was based on clinical symptoms and signs and electrophysiology as per the Toronto consensus definition (2). Both the index test and the reference standard were undertaken in

participants at baseline and annual follow-up visits. The staff performing the reference standard were blinded to results of the index test (and vice versa). This article follows the 2015 Standards for Reporting of Diagnostic Accuracy statement (10).

### Study Population

This analysis creates a “neuropathy incidence cohort” from a subset of the original cohort established by the consortium (6). In brief, 998 people with diabetes (432 adults and 84 adolescents with type 1 diabetes and 482 adults with type 2 diabetes) completed baseline evaluations between 2008 and 2011. Participants were recruited from local diabetes, endocrinology, and neurology clinics, had type 1 or type 2 diabetes (in accordance with American Diabetes Association guidelines), and had unknown DPN status at the time of initial contact. Exclusion criteria included neuropathy due to nondiabetic causes, current eye infection or other conditions that precluded CCM, and allergy to the ocular anesthetic used during the CCM examination. The protocol and consent procedures at all sites were approved by local research ethics boards, and written informed consent was provided by all study participants or their legal guardians.

### CCM Examination (Index Test)

Participants underwent examination of the subbasal nerve plexus of the cornea using the Heidelberg Tomograph Rostock Cornea Module III (Heidelberg Engineering GmbH, Heidelberg, Germany, and Heidelberg Engineering, Smithfield, RI) according to published methods. The device is a laser scanning in vivo confocal microscope that uses a visible 670-nm red wavelength diode laser source to highlight the area of the cornea being scanned for the examiner and to illuminate its structures. In brief, after application of topical anesthetic eye drops, a viscous gel medium was applied, permitting a visual gel bridge between the cornea and the sterile single-use cap on the microscope’s objective lens. Subjects fixed their gaze on a target positioned behind the CCM device, and the examiner used a side view digital video camera to ensure that the apex—or the central area—of the cornea was scanned. The examiner manually focused the CCM

lens on the subbasal nerve plexus adjacent to the Bowman layer of the cornea and captured the first in-focus high-contrast image. Images were taken through the subbasal layer over a depth of ~60  $\mu\text{m}$  using methods that had minor procedural variation between centers (11). Six to eight images of the central subbasal nerve plexus were selected by site staff according to quality, position, and depth, and CCM parameters were determined using an automated protocol (ACCMetrics software) (12). Measured parameters were CNFL, expressed as the total length of nerves in  $\text{mm}/\text{mm}^2$  of image area; corneal nerve branch density (CNBD), expressed as  $\text{branches}/\text{mm}^2$ ; and corneal nerve fiber density (CNFD), expressed as  $\text{fibers}/\text{mm}^2$ . CCM operators were either trained in optometry or ophthalmology or were research assistants who underwent training by the microscope manufacturer. Published data have demonstrated similar cohort in vivo CCM characteristics, reproducibility, and concurrent validity, regardless of study site (4,6,11,13–19). For sensitivity analysis, we examined corneal nerve fiber area (CNFA), and manual CNFL (CNFL<sub>Manual</sub>) at the baseline visit.

### Neuropathic Symptoms, Deficits, and Electrophysiology (Reference Standard)

All participants were free of DPN at baseline, and incident DPN was defined at the first follow-up visit using the following criteria based on the Toronto consensus: the presence of one or more neuropathic symptoms and/or the presence of two or more signs of neuropathy corroborated by the presence of electrophysiological abnormality in the lower limbs (2,20). For determination of neuropathic symptoms, the Queensland site used the Diabetic Neuropathy Symptom (DNS) scoring system, the Calgary site used the Neuropathy Symptom Score (NSS) system, the Manchester site used the Neuropathy Symptom Profile (NSP), and the Toronto site used the Toronto Clinical Neuropathy Score (TCNS) symptom subscale (6). For neuropathic signs, comprehensive neurological examination was operationalized at the Toronto site using the TCNS sign subscale system; all other sites used the Neuropathy Disability Score (NDS) system (6). An algorithm was applied to the patient-level data to determine DPN status (both at baseline and during follow-

up). Additional details of the methods used to define DPN can be found in our consortium's baseline article and its supplementary materials (6).

### Statistical Analysis

Between-group comparisons of clinical and DPN characteristics were made using ANOVA, the Kruskal-Wallis test, or the  $\chi^2$  test (depending on distribution). For each participant, the change in clinical and neuropathic variables over follow-up was calculated as the difference between the baseline and final follow-up observation. To account for censoring and varying length of follow-up, the predictive diagnostic validity of CCM was determined using time-dependent receiver operating characteristic (ROC) curves. Time-dependent ROC curves are constructed using methods that extend standard cross-sectional ROC curves into the longitudinal setting using survival analysis techniques. The incident cases/dynamic controls method of Heagerty and colleagues (21,22) was used to construct the time-dependent ROC curves. In this setting, the ROC curve at time  $t$  compares CCM parameters of incident cases with new-onset DPN at time  $t$  to all control subjects who remained DPN free through time  $t$ . The corresponding area under the ROC curve at time  $t$  [AUC( $t$ )] can then be interpreted as the probability that a random incident case subject who experienced the event at time  $t$  had a lower CCM parameter value than a random control subject who remained event free through time  $t$  (assuming that both are event free up to time  $t$ ). As an estimate of overall concordance between the index test and reference standard, Harrell C-statistic was calculated. Baseline CCM measurements were used to determine AUC( $t$ ) and the C-statistic. The crude area under the curve (AUC) using ROC curves ignoring time was also calculated for comparison with AUC( $t$ ). Optimal diagnostic threshold values were determined by finding the point on the ROC curves closest to the upper-left-hand corner of the plot.

A priori, the recruitment goal called for 70% of the baseline cohort to be followed for 4–8 years; this planned sample size would be sufficient to detect a crude AUC of 0.70 (representing good predictive validity). At study closeout,

261 participants without DPN at baseline had at least 4 years of follow-up (62% of planned sample size). The planned analysis called for stratification by diabetes type. We included two sensitivity analyses. First, as an alternative to restricting the analysis to the baseline CCM parameters only, time-updated CCM values (taken during follow-up) were used to calculate AUC( $t$ ). Second, we included a pooled type 1 and type 2 diabetes analysis. An  $\alpha$ -level of 0.05 was used for tests of statistical significance. Time-dependent ROC curve analysis was performed using the R software environment ("meanrankROC" package) (22). All other statistical analyses were performed using SAS version 9.4.

### RESULTS

A study flow diagram is presented in Supplementary Fig. 1. Of the 998 participants with a valid index test and reference standard data included in the baseline concurrent validity study, 415 had DPN at baseline while 583 did not. There were 387 of 583 (66%) participants without DPN who had at least one follow-up visit with valid reference standard data; 261 of 387 had at least 4 years of follow-up and were eligible for analysis.

Baseline characteristics of the 261 participants included in the primary analysis are shown in Table 1. There were 203 (78%) participants with type 1 diabetes and 58 (22%) with type 2 diabetes. These two groups differed in their demographic and clinical disposition, and the type 1 diabetes subcohort had lower mean age ( $36 \pm 19$  vs.  $60 \pm 7$  years;  $P < 0.001$ ) and higher HbA<sub>1c</sub> ( $8.2 \pm 1.5$  vs.  $7.3 \pm 1.0\%$ ;  $P < 0.001$ ). Although no participants met the reference standard definition for neuropathy at baseline, participants with type 2 diabetes had a higher prevalence of DPN signs and/or symptoms, lower sural nerve amplitude and conduction velocity, and lower peroneal nerve F-wave latency. Baseline CNFL was significantly lower in the type 2 diabetes subcohort compared with the type 1 diabetes subcohort ( $13.6 \pm 3.6$  vs.  $15.3 \pm 3.6$  mm/mm<sup>2</sup>;  $P = 0.003$ ).

In the primary analysis set, mean  $\pm$  SD follow-up time was  $5.8 \pm 1.6$  years (median 6.0 years [interquartile range 4.2–7.0]) over a median of five visits

(interquartile range 3–5). New-onset DPN was present in 60 participants (cumulative incidence rate 23%; incidence rate 4.29 events per 100 person-years). Clinical characteristics at baseline and their change over the follow-up period are shown for participants without DPN and case subjects with new-onset DPN in Table 2. Participants who developed DPN were older and had a higher BMI, higher prevalence of type 2 diabetes, and longer duration of diabetes. The baseline electrophysiology results were mainly in the normal ranges, but participants who developed DPN had significantly more impaired values compared with controls. Baseline CCM parameters were all significantly lower in participants who developed DPN. The mean values for CCM parameters were relatively stable over follow-up in both groups.

Details of the predictive diagnostic validity analysis—performed using time-dependent ROC curves—are shown in Table 3, which provides the estimates of AUC( $t$ ) at years 2, 3, 4, 5, and 6; the estimate of crude AUC; and the C-statistic for each of the index tests. We highlight the following observations: First, in the type 1 and type 2 diabetes subcohorts and pooled data set, CNFL numerically had the highest AUC( $t$ ) and crude AUC among the CCM parameters. Second, AUC( $t$ ) values for CNFL tended to be higher in type 1 diabetes compared with type 2 diabetes, and AUC( $t$ ) values were highest at year 5 or 6. Third, the overall C-statistic for CNFL was 0.63 in the type 1 and type 2 diabetes subcohorts and in the pooled data set; the 95% CI did not include the value 0.50 in the three groups, indicating moderate, but statistically significant overall predictive diagnostic validity. Fourth, as part of the sensitivity analysis, the time-varying CCM parameters had similar or lower AUC( $t$ ) and C-statistic values compared with the baseline parameters.

In the type 1 diabetes derivation set, the optimal threshold of CNFL for identifying new-onset DPN was 13.9 mm/mm<sup>2</sup> at 2 years and 14.1 mm/mm<sup>2</sup> at years 3–6. The optimal threshold for the crude ROC curve was 14.1 mm/mm<sup>2</sup>. These values were confirmed in the type 2 diabetes validation set, with values of 14.2 mm/mm<sup>2</sup> at years 2–5, 14.9 mm/mm<sup>2</sup> at year 6, and a crude estimate of 14.1 mm/mm<sup>2</sup>. In the pooled data set, the optimal threshold value

**Table 1—Baseline characteristics of the study participants without DPN at baseline for the total cohort and the type 1 and type 2 diabetes subcohorts.**

Characteristic	Total (N = 261)	Type 1 diabetes (n = 203)	Type 2 diabetes (n = 58)	P value
<b>Clinical and demographic variables</b>				
Age, years	41 ± 19	36 ± 19	60 ± 7	<0.001
Age <18 years, n (%)	59 (23)	59 (29)	0 (0)	—
Female sex, n (%)	128 (49)	100 (49)	28 (48)	0.89
Diabetes duration, years	15 ± 12	16 ± 12	12 ± 7	0.073
BMI, kg/m <sup>2</sup>	26.0 ± 5.3	24.9 ± 4.7	30.3 ± 5.3	<0.001
HbA <sub>1c</sub> , %	8.0 ± 1.5	8.2 ± 1.5	7.3 ± 1.0	<0.001
HbA <sub>1c</sub> , mmol/mol	64 ± 16	66 ± 16	56 ± 11	<0.001
LDL cholesterol, mmol/L	2.39 ± 0.79	2.48 ± 0.80	2.06 ± 0.70	<0.001
eGFR, mL/min/1.73 m <sup>2</sup> *	78 ± 14	78 ± 11	79 ± 20	0.73
<b>Neuropathy measurements</b>				
Signs and/or symptoms present, n (%)	92 (35)	50 (25)	42 (72)	<0.001
Sural nerve amplitude, μV	12.7 ± 8.7	13.5 ± 9.0	9.7 ± 6.9	0.002
Sural nerve conduction velocity, m/s	42.5 ± 7.3	42.0 ± 7.0	44.2 ± 8.0	0.017
Peroneal nerve amplitude, mV	4.9 ± 2.4	5.0 ± 2.4	4.5 ± 2.1	0.16
Peroneal nerve conduction velocity, m/s	46.0 ± 5.7	45.9 ± 5.7	46.1 ± 6.1	0.69
Peroneal nerve F-wave latency, ms	54.5 ± 10.2	55.8 ± 10.8	51.1 ± 7.4	0.007
<b>Automated CCM measures</b>				
CNFL, mm/mm <sup>2</sup> †	14.9 ± 3.7	15.3 ± 3.6	13.6 ± 3.6	0.003
CNBD, branches/mm <sup>2</sup>	26.3 ± 16.3	26.3 ± 16.4	26.6 ± 16.0	0.91
CNFD, fibers/mm <sup>2</sup>	21.2 ± 8.0	21.2 ± 7.6	21.1 ± 9.5	0.98

Data are mean ± SD unless otherwise indicated. P values are for comparison between type 1 and type 2 diabetes subcohorts. eGFR, estimated glomerular filtration rate. \*At baseline and follow-up, no participants had kidney failure (renal replacement therapy or eGFR <15 mL/min/1.73 m<sup>2</sup>). eGFR <60 mL/min/1.73 m<sup>2</sup> occurred in 30 (11%) participants over the course of follow-up. This represented 12 participants with eGFR <60 mL/min/1.73 m<sup>2</sup> at baseline, no participants with eGFR <30 mL/min/1.73 m<sup>2</sup> at baseline, and 1 participant with 15 < eGFR < 30 mL/min/1.73 m<sup>2</sup> over the course of follow-up. †On the basis of our previous work on concurrent validity in individuals with diabetes (6), we identified a CNFL of 8.6 mm/mm<sup>2</sup> as abnormal. In the current study, we found that 16 of 261 (6%) individuals had a CNFL ≤8.6 mm/mm<sup>2</sup>. The onset of large fiber damage was defined by the development of DPN and ranged from 3 to 5 years. Indeed, the group with baseline CNFL <8.6 mm/mm<sup>2</sup> had a higher incidence of DPN (7 of 16, 44%) and a shorter time to DPN onset than those with a CNFL >8.6 mm/mm<sup>2</sup> (3 vs. 5 years).

was 14.1 mm/mm<sup>2</sup> at all time points; values below this threshold had a hazard ratio for developing new-onset DPN of 2.95 (95% CI 1.70–5.11; *P* < 0.001) compared with those above this threshold. The Kaplan-Meier curves illustrating this hazard ratio are shown in Fig. 1. The optimal threshold value corresponded to an overall sensitivity of 67%, specificity of 71%, positive diagnostic likelihood ratio of 2.26, and negative diagnostic likelihood ratio of 0.46.

## CONCLUSIONS

This large, multinational, longitudinal diagnostic study has shown that CCM has significant predictive diagnostic validity for identifying patients with type 1 and type 2 diabetes at higher risk of new-onset DPN ~6 years in the future. Participants who developed DPN had a higher prevalence of symptoms and signs, more abnormal sural and peroneal nerve electrophysiology, and lower CNFD, CNBD, CNFL, and CNFA at

baseline. Furthermore, the predictive diagnostic validity of CNFL was relatively stable over the follow-up period and was associated with a nearly threefold risk of developing new-onset DPN.

CCM has been used to identify a subclinical reduction in corneal nerve fibers with a comparable utility to quantitative sensory testing and electrophysiology in diagnosing patients with DPN (4,23,24). In a large, multinational cohort of patients with type 1 and type 2 diabetes, we also established the diagnostic validity and thresholds for CNFL in the diagnosis of DPN (6). In relation to concurrent validity, a CNFL value <8.6 mm/mm<sup>2</sup> was associated with a specificity of 88% and a positive likelihood ratio of ~3.0 for DPN, while a CNFL value >15.3 mm/mm<sup>2</sup> was associated with a sensitivity of 88% and negative likelihood ratio of ~0.3. Values between 8.6 and 15.3 mm/mm<sup>2</sup> represented future risk of DPN. Our current study of predictive validity demonstrates that values

<14.1 mm/mm<sup>2</sup> represent the greatest risk for future-onset DPN. Though not confirmed by independent studies, these numbers arose from the largest neuropathy cohort for CCM, and they propose practical thresholds to define the presence, the absence, and the future risk for DPN for use in future clinical diagnostic research studies.

One may argue that an AUC of ~70% represents modest performance; however, the reference standard for identifying DPN was for more advanced large fiber damage rather than early subclinical DPN associated with small fiber damage. Furthermore, the relative risk of developing DPN varies according to risk factors and ongoing treatment, which may well impact on the predictive validity of any test. In the current study the development of DPN was associated with older age, type 2 diabetes, a longer duration of diabetes, and higher BMI. Indeed, the development of DPN may be determined by multiple

**Table 2—Baseline and change in clinical variables and neuropathy and CCM measures in participants who did and did not develop DPN**

Characteristic	Did not develop DPN (n = 201)	Developed DPN (n = 60)	P value
<b>Baseline clinical variables†</b>			
Age, years	43 ± 20	59 ± 15	<0.001
Type 1 diabetes, n (%)	166 (83)	37 (62)	<0.001
Type 2 diabetes, n (%)	35 (17)	23 (38)	
Female sex, n (%)	103 (51)	25 (42)	0.19
Diabetes duration, years	19 ± 11	25 ± 14	0.001
BMI, kg/m <sup>2</sup>	26.1 ± 4.3	28.4 ± 5.6	0.006
HbA <sub>1c</sub> , %	7.9 ± 1.6	7.7 ± 1.2	0.33
HbA <sub>1c</sub> , mmol/mol	63 ± 18	61 ± 13	0.33
LDL cholesterol, mmol/L	2.34 ± 0.79	2.20 ± 0.74	0.36
<b>Change in clinical variables†</b>			
BMI, kg/m <sup>2</sup>	0.8 ± 2.6	−0.2 ± 2.4	0.013
HbA <sub>1c</sub> , %	−0.1 ± 1.4	0.0 ± 1.0	0.50
HbA <sub>1c</sub> , mmol/mol	−1 ± 15	0 ± 11	0.50
LDL cholesterol, mmol/L	−0.01 ± 0.77	−0.40 ± 0.87	0.014
<b>Baseline neuropathy measurements</b>			
Signs and/or symptoms present, n (%)	58 (29)	34 (57)	<0.001
Sural nerve amplitude, μV	12.0 ± 7.7	7.0 ± 6.4	<0.001
Sural nerve conduction velocity, m/s	45.0 ± 7.1	38.7 ± 6.6	<0.001
Peroneal nerve amplitude, mV	5.3 ± 2.2	3.5 ± 2.2	<0.001
Peroneal nerve conduction velocity, m/s	45.7 ± 3.9	38.6 ± 4.2	<0.001
Peroneal nerve F-wave latency, ms	52.5 ± 9.3	61.3 ± 10.4	<0.001
<b>Change in neuropathy measurements†</b>			
Increase in number of signs and/or symptoms, n (%)	16 (8)	26 (43)	<0.001
Sural nerve amplitude, μV	−2.0 ± 8.5	−0.8 ± 5.8	0.24
Sural nerve conduction velocity, m/s	1.5 ± 7.1	−0.2 ± 5.9	0.095
Peroneal nerve amplitude, mV	0.2 ± 2.2	−0.4 ± 2.1	0.056
Peroneal nerve conduction velocity, m/s	−1.6 ± 5.0	−2.8 ± 5.7	0.11
Peroneal nerve F-wave latency, ms	1.2 ± 11.1	3.7 ± 9.2	0.14
<b>Baseline CCM measurements</b>			
CNFL, mm/mm <sup>2</sup>	15.5 ± 3.4	13.2 ± 4.0	<0.001
CNBD, branches/mm <sup>2</sup>	27.5 ± 15.8	22.7 ± 17.6	0.049
CNFD, fibers/mm <sup>2</sup>	22.2 ± 7.9	17.8 ± 7.6	<0.001
CNFL <sub>Manual</sub> , mm/mm <sup>2</sup>	19.8 ± 5.9	17.6 ± 5.6	0.012
CNFA, μm/mm <sup>2</sup>	22,197 ± 8,132	18,558 ± 7,565	0.002
<b>Change in CCM measurements†</b>			
CNFL, mm/mm <sup>2</sup>	0.0 ± 3.1	−0.3 ± 3.9	0.53
CNBD, branches/mm <sup>2</sup>	1.8 ± 16.5	−1.6 ± 14.6	0.16
CNFD, fibers/mm <sup>2</sup>	0.1 ± 7.7	0.0 ± 8.8	0.94

Data are mean ± SD unless otherwise indicated. †Expressed as difference from baseline to final follow-up visit (or first visit where new onset was apparent).

factors, including hyperglycemia-driven abnormalities of the polyol pathway, advanced glycation end products, and dyslipidemia (25). Furthermore, high BMI, hypertension, and cholesterol and triglyceride levels are associated with incident DPN in type 1 diabetes (26), and age, BMI, waist circumference, LDL cholesterol, and HDL cholesterol are associated with incident DPN in type 2 diabetes (27). Treatment with fibrates and statin therapy is associated with a reduced incidence of DPN (28), and increased triglycerides are associated

with incident DPN (29) and amputation (30). There are also differences in risk factors for corneal nerve loss between patients with type 1 and type 2 diabetes (31–33). Thus, a longer duration of diabetes has been associated with reduced CNFD and CNBD in patients with type 1 diabetes (34), while higher LDL and total cholesterol was related to lower CNFD and CNFL in patients with type 2 diabetes (27). More recently, we have shown a significant association of reduced CNFL with age, HbA<sub>1c</sub>, and weight in patients with type 2 diabetes

and with duration of diabetes, LDL cholesterol, and triglycerides in patients with type 1 diabetes (35). Indeed, normalization of blood glucose following simultaneous pancreas and kidney transplantation (36), improvement in HbA<sub>1c</sub> with basal bolus insulin or glucagon-like peptide 1 therapy (37), and bariatric surgery are associated with a significant improvement in corneal nerve morphology (38).

We acknowledge several limitations to our study. First, the sample size did not permit independent validation sets

**Table 3—Area under the ROC curve values at selected time points and overall concordance statistic for each CCM parameter**


Set and parameter	Area under the ROC curve						C-statistic (95% CI)
	Crude estimate	2 years	3 years	4 years	5 years	6 years	
<b>Pooled</b>							
<b>Baseline</b>							
CNFL	0.69	0.67	0.61	0.62	0.69	0.80	0.63 (0.54–0.72)
CNBD	0.62	0.52	0.47	0.52	0.56	0.66	0.57 (0.47–0.67)
CNFD	0.67	0.62	0.59	0.56	0.46	0.51	0.63 (0.54–0.72)
CNFL <sub>Manual</sub>	0.61	0.49	0.50	0.49	0.52	0.59	0.56 (0.47–0.65)
CNFA	0.64	0.55	0.46	0.46	0.59	0.76	0.59 (0.49–0.68)
<b>Time varying</b>							
CNFL	—	0.70	0.60	0.60	0.66	0.75	0.63 (0.54–0.72)
CNBD	—	0.60	0.53	0.53	0.56	0.65	0.59 (0.504–0.68)
CNFD	—	0.62	0.57	0.58	0.43	0.46	0.61 (0.52–0.70)
<b>Type 1 diabetes</b>							
<b>Baseline</b>							
CNFL	0.67	0.67	0.54	0.56	0.91	0.85	0.63 (0.51–0.75)
CNBD	0.61	0.42	0.45	0.50	0.76	0.76	0.55 (0.42–0.67)
CNFD	0.65	0.65	0.50	0.54	0.51	0.58	0.63 (0.51–0.74)
CNFL <sub>Manual</sub>	0.60	0.41	0.58	0.55	0.47	0.49	0.54 (0.43–0.65)
CNFA	0.63	0.57	0.43	0.44	0.61	0.73	0.56 (0.44–0.68)
<b>Time varying</b>							
CNFL	—	0.72	0.50	0.51	0.86	0.73	0.63 (0.52–0.74)
CNBD	—	0.61	0.49	0.49	0.79	0.72	0.59 (0.48–0.69)
CNFD	—	0.72	0.54	0.54	0.50	0.49	0.63 (0.52–0.73)
<b>Type 2 diabetes</b>							
<b>Baseline</b>							
CNFL	0.71	0.60	0.63	0.65	0.62	0.75	0.63 (0.503–0.76)
CNBD	0.69	0.66	0.57	0.61	0.56	0.62	0.62 (0.47–0.77)
CNFD	0.72	0.71	0.58	0.56	0.53	0.48	0.61 (0.45–0.76)
CNFL <sub>Manual</sub>	0.66	0.56	0.64	0.68	0.65	0.69	0.59 (0.45–0.74)
CNFA	0.65	0.54	0.58	0.63	0.64	0.78	0.64 (0.51–0.78)
<b>Time varying</b>							
CNFL	—	0.55	0.59	0.61	0.61	0.75	0.63 (0.49–0.77)
CNBD	—	0.59	0.51	0.55	0.50	0.61	0.59 (0.45–0.73)
CNFD	—	0.65	0.52	0.50	0.46	0.48	0.57 (0.43–0.71)

for type 1 and type 2 diabetes as it did for our prior evaluation of concurrent validity (6). While validation in separate cohorts is important, the similar diagnostic thresholds regardless of diabetes

type and overall AUC in this cohort and the baseline cohort assure us that our estimates are stable. Second, we acknowledge the possible presence of selection bias as participants most likely to

volunteer for this study may have had a greater likelihood of early neuropathic symptoms despite not meeting diagnostic criteria for neuropathy and, thus, were more likely to have new-onset neuropathy at follow-up. Finally, there were small variations in the CCM image acquisition protocols, though image selection for analysis was undertaken by the same investigator (M.F.) on the basis of our established criteria (39).

In conclusion, systematic results of a neuropathy incidence cohort demonstrate that CCM represents a rapid, non-invasive, small nerve fiber imaging technique to identify patients with type 1 or type 2 diabetes at higher future risk of developing DPN over 6 years of follow-up. This study provides further support for the utility of CCM as a means to identify populations at high risk of neuropathy onset for clinical



**Figure 1—Kaplan-Meier curves for neuropathy-free survival according to baseline CNFL level. The blue line represents higher CNFL levels at baseline, and the red line represents lower. The vertical hash marks represent censored observations. Number at risk is given at the bottom of the graph.**

research and in clinical practice and supports its value as a surrogate marker for nerve injury in DPN.

**Funding.** This study was supported by funding from the National Institutes of Health (grant 1DP3-DK-104386-01). B.A.P. holds the Sam and Judy Pencer Family Chair in Diabetes Clinical Research, University of Toronto. The authors acknowledge the generous support of Randy and Jenny Frisch and the Harvey and Annice Frisch Family Fund, the Menkes Family Fund, David and Jill Wright, and BMO for supporting aspects of this research in Toronto. L.E.L. receives support from a Canadian Institute for Health Research (CIHR) Canada Graduate Scholarship Doctoral Award. E.J.H.L. reports grants from CIHR.

**Duality of Interest.** B.A.P. has received speaker honoraria from Abbott, Medtronic, Insulet, and Novo Nordisk and support to his research institute from Boehringer Ingelheim and the Bank of Montreal and has served as a consultant to Boehringer Ingelheim, Abbott, and Novo Nordisk. E.J.H.L. is part owner of Nutarniq Corp., which researches and develops targeted nutritional therapies for chronic diseases and disease complications. V.B. has served as a consultant for UCB, Alnylam, Akcea, Alexion, Immunovant, Takeda, Novo Nordisk, and Argenx; has served on advisory boards for these and Sanofi, Janssen, and Momenta; and receives research support at this time from UCB, Alexion, and Takeda. R.A.M. has received speaker honoraria from Novo Nordisk, Pfizer, Aventis, and Eli Lilly and support to his research institution from Pfizer and Proctor & Gamble. No other potential conflicts of interest relevant to this article were reported.

**Author Contributions.** B.A.P., L.E.L., E.J.H.L., and R.A.M. wrote the first draft of the manuscript. B.A.P., V.B., N.E., and R.A.M. designed the study. L.E.L. carried out the data analysis, including the statistical analyses. M.F., A.O., K.E., N.P., A.R., C.D., D.P., K.R., J.K.M., M.J., A.M., R.M.S., R.P.-B., S.I.L., M.T., A.J.M.B., N.E., and R.A.M. conducted the study. All authors reviewed the manuscript for scholarly content and accuracy, and all authors read and approved the final version of the manuscript. B.A.P. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Prior Presentation.** Parts of this study were presented in abstract form at the 79th Scientific Sessions of the American Diabetes Association, San Francisco, CA, 7–11 June 2019, and at the 29th Annual Meeting of the Diabetic Neuropathy Study Group, Barcelona, Spain, 13–19 September 2019.

## References

1. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. *Diabetes Care* 2017;40:136–154

2. Tesfaye S, Boulton AJ, Dyck PJ, et al.; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care* 2010;33:2285–2293

3. Breiner A, Lovblom LE, Perkins BA, Bril V. Does the prevailing hypothesis that small-fiber dysfunction precedes large-fiber dysfunction apply to type 1 diabetic patients? *Diabetes Care* 2014;37:1418–1424

4. Chen X, Graham J, Dabbah MA, et al. Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. *Diabetes Care* 2015;38:1138–1144

5. Sivakandarajah GA, Halpern EM, Lovblom LE, et al. Structure-function relationship between corneal nerves and conventional small-fiber tests in type 1 diabetes. *Diabetes Care* 2013;36:2748–2755

6. Perkins BA, Lovblom LE, Bril V, et al. Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. *Diabetologia* 2018;61:1856–1861

7. Lewis E, Lovblom LE, Ferdousi M, et al. Rapid corneal nerve fiber loss: a marker of diabetic neuropathy onset and progression. *Diabetes Care* 2020;43:1829–1835

8. Pritchard N, Edwards K, Russell AW, Perkins BA, Malik RA, Efron N. Corneal confocal microscopy predicts 4-year incident peripheral neuropathy in type 1 diabetes. *Diabetes Care* 2015;38:671–675

9. Lovblom LE, Halpern EM, Wu T, et al. In vivo corneal confocal microscopy and prediction of future incident neuropathy in type 1 diabetes: a preliminary longitudinal analysis. *Can J Diabetes* 2015;39:390–397

10. Bossuyt PM, Reitsma JB, Bruns DE, et al.; STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ* 2015;351:h5527

11. Hume DA, Lovblom LE, Ahmed A, et al. Higher magnification lenses versus conventional lenses for evaluation of diabetic neuropathy by corneal in vivo confocal microscopy. *Diabetes Res Clin Pract* 2012;97:e37–e40

12. Chen X, Graham J, Dabbah MA, Petropoulos IN, Tavakoli M, Malik RA. An automatic tool for quantification of nerve fibers in corneal confocal microscopy images. *IEEE Trans Biomed Eng* 2017;64:786–794

13. Ferdousi M, Kalteniece A, Petropoulos I, et al. Diabetic neuropathy is characterized by progressive corneal nerve fiber loss in the central and inferior whorl regions. *Invest Ophthalmol Vis Sci* 2020;61:48

14. Ahmed A, Bril V, Orszag A, et al. Detection of diabetic sensorimotor polyneuropathy by corneal confocal microscopy in type 1 diabetes: a concurrent validity study. *Diabetes Care* 2012;35:821–828

15. Halpern EM, Lovblom LE, Orlov S, Ahmed A, Bril V, Perkins BA. The impact of common variation in the definition of diabetic sensorimotor polyneuropathy on the validity of corneal in vivo confocal microscopy in patients with type 1 diabetes: a brief report. *J Diabetes Complications* 2013;27:240–242

16. Ostrovski I, Lovblom LE, Farooqi MA, et al. Reproducibility of in vivo corneal confocal microscopy using an automated analysis program for detection of diabetic sensorimotor polyneuropathy. *PLoS One* 2015;10:e0142309

17. Stem MS, Hussain M, Lentz SI, et al. Differential reduction in corneal nerve fiber length in patients with type 1 or type 2 diabetes mellitus. *J Diabetes Complications* 2014;28:658–661

18. Pacaud D, Romanchuk KG, Tavakoli M, et al. The reliability and reproducibility of corneal confocal microscopy in children. *Invest Ophthalmol Vis Sci* 2015;56:5636–5640

19. Scarr D, Lovblom LE, Ostrovski I, et al. Agreement between automated and manual quantification of corneal nerve fiber length: implications for diabetic neuropathy research. *J Diabetes Complications* 2017;31:1066–1073

20. England JD, Gronseth GS, Franklin G, et al.; American Academy of Neurology; American Association of Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. *Neurology* 2005;64:199–207

21. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. *Biometrics* 2005;61:92–105

22. Bansal A, Heagerty PJ. A tutorial on evaluating the time-varying discrimination accuracy of survival models used in dynamic decision making. *Med Decis Making* 2018;38:904–916

23. Malik RA, Kallinikos P, Abbott CA, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. *Diabetologia* 2003;46:683–688

24. Ferdousi M, Kalteniece A, Azmi S, et al. Corneal confocal microscopy compared with quantitative sensory testing and nerve conduction for diagnosing and stratifying the severity of diabetic peripheral neuropathy. *BMJ Open Diabetes Res Care* 2020;8:e001801

25. Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. *Neuron* 2017;93:1296–1313

26. Tesfaye S, Chaturvedi N, Eaton SE, et al.; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. *N Engl J Med* 2005;352:341–350

27. Andersen ST, Witte DR, Dalsgaard EM, et al. Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark. *Diabetes Care* 2018;41:1068–1075

28. Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. *Diabetologia* 2008;51:562–566

29. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. *Diabetes* 2009;58:1634–1640

30. Callaghan BC, Feldman E, Liu J, et al. Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. *Diabetes Care* 2011;34:635–640

31. Dehghani C, Pritchard N, Edwards K, Russell AW, Malik RA, Efron N. Risk factors associated with corneal nerve alteration in type 1 diabetes in the absence of neuropathy: a longitudinal in vivo corneal confocal microscopy study. *Cornea* 2016;35:847–852

32. Andersen ST, Grosen K, Tankisi H, et al. Corneal confocal microscopy as a tool for detecting diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes: ADDITION-Denmark. *J Diabetes Complications* 2018;32:1153–1159
33. Ishibashi F, Okino M, Ishibashi M, et al. Corneal nerve fiber pathology in Japanese type 1 diabetic patients and its correlation with antecedent glycemic control and blood pressure. *J Diabetes Investig* 2012;3:191–198
34. Dehghani C, Pritchard N, Edwards K, et al. Natural history of corneal nerve morphology in mild neuropathy associated with type 1 diabetes: development of a potential measure of diabetic peripheral neuropathy. *Invest Ophthalmol Vis Sci* 2014;55:7982–7990
35. Ferdousi M, Kalteniece A, Azmi S, et al. Diagnosis of neuropathy and risk factors for corneal nerve loss in type 1 and type 2 diabetes: a corneal confocal microscopy study. *Diabetes Care* 2021;44:150–156
36. Azmi S, Jeziorska M, Ferdousi M, et al. Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. *Diabetologia* 2019;62:1478–1487
37. Ponirakis G, Abdul-Ghani MA, Jayyousi A, et al. Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study. *BMJ Open Diabetes Res Care* 2020;8:e001420
38. Adam S, Azmi S, Ho JH, et al. Improvements in diabetic neuropathy and nephropathy after bariatric surgery: a prospective cohort study. *Obes Surg* 2021;31:554–563
39. Kalteniece A, Ferdousi M, Adam S, et al. Corneal confocal microscopy is a rapid reproducible ophthalmic technique for quantifying corneal nerve abnormalities. *PLoS One* 2017;12:e0183040